CKS2 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a full length recombinant CKS2.
- 产品详情
- 实验流程
- 背景知识
Application
| WB, IF, E |
|---|---|
| Primary Accession | P33552 |
| Other Accession | BC006458 |
| Reactivity | Human |
| Host | mouse |
| Clonality | monoclonal |
| Isotype | IgG2b kappa |
| Clone Names | 2H5-2C4 |
| Calculated MW | 9860 Da |
| Gene ID | 1164 |
|---|---|
| Other Names | Cyclin-dependent kinases regulatory subunit 2, CKS-2, CKS2 |
| Target/Specificity | CKS2 (AAH06458, 1 a.a. ~ 79 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
| Dilution | WB~~1:500~1000 IF~~1:50~200 E~~N/A |
| Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
| Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
| Precautions | CKS2 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
CKS2 protein binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function. The CKS2 mRNA is found to be expressed in different patterns through the cell cycle in HeLa cells, which reflects specialized role for the encoded protein.
REFERENCES
Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma. Shen DY, et al. Liver Int, 2010 Jan. PMID 19845855.Upregulation of the cycline kinase subunit CKS2 increases cell proliferation rate in gastric cancer. Kang MA, et al. J Cancer Res Clin Oncol, 2009 Jun. PMID 19034516.Cyclin-dependent kinase-associated proteins Cks1 and Cks2 are essential during early embryogenesis and for cell cycle progression in somatic cells. Martinsson-Ahlz?n HS, et al. Mol Cell Biol, 2008 Sep. PMID 18625720.Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Lan Y, et al. Int J Cancer, 2008 Aug 1. PMID 18498131.Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. Bertheau P, et al. PLoS Med, 2007 Mar. PMID 17388661.
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。